Anosmia Clinical Trials 2023

Browse 5 Anosmia Medical Studies Across 5 Cities

5 Anosmia Clinics

Clinical TrialsAnosmia Clinical Trials 2023
Reviewed by Michael Gill, B. Sc.
Image of Michelle Orzechowski in Tampa, United States.

Aerosolized 13 Cis Retinoic Acid And Vitamin Dfor Anomia

18 - 70
All Sexes
Tampa, FL
Investigating the potential role of Aerosolized retinoic acid, a potent Vitamin A metabolite for treating COVID-19 Anosmia and retinoic acid insufficiency .A novel approach for regaining Sense of Smell. Mahmoud ELkazzaz(1),Tamer Haydara(2), Abedelaziz Elsayed(3) ,Yousry Abo-amer(4), Hesham Attia(5), Quan Liu(6) and Amr Ahmed(7) Department of chemistry and biochemistry, Faculty of Science, Damietta University, Egypt. Department of Internal Medicine, Faculty of Medicine, Kafrelsheikh University, Egypt Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tanta University, Egypt. Hepatology,Gastroenterology and Infectious Diseases Department, Mahala Hepatology Teaching Hospital, Egypt Department of Immunology and Parasitology, Faculty of Science, Cairo University, Egypt. School of Life Sciences and Engineering, Foshan University, Laboratory of Emerging Infectious Disease, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China. Director of tuberculosis program Ghubera, public health department ,First health cluster ,Ministry of health ,Saudia Arabia. Very important Note: This clinical study is the first clinical study in literature (First posted August 12, 2021) which demonstrated depending on molecular findings that Vitamin A /Retinoic Acid will treat smell loss resulted by COVID-19 Recent rapidly accumulating evidences and reports indicate that partial loss of the sense of smell or even total anosmia are early markers of SARS-CoV-2 infection and frequently reported symptoms associated with the COVID-19 pandemic (Lechien J. R et al., 2020) However, the cellular mechanisms of this phenomenon are unknown. The rates of insomnia and depression were 26.45% and 9.92% in the COVID-19 patients after recovery. Therefore, finding an effective treatment for COVID-19 Anosmia is a critical point. Although, ACE2 has been identified as the principal host cell receptor of 2019-nCoV, and it is thought to play a critical role in the virus's entrance into the cell and subsequent infection, many cells can be infected by COVID-19 while also expressing little or no ACE2. Even though the COVID-19 entry receptor, angiotensin-converting enzyme 2 (ACE2), is not expressed in the receptor of olfactory neurons, or its synthesis is limited to to a minor fraction of these neurons.of these neurons, COVID-19 infection causes a loss of smell (anosmia) (Katarzyna Bilinska et al.,2021). Our recent findings showed that COVID-19 binds directly to STRA6 receptors of retinol leading to retinol depletion and retinoic acid insufficiency (M Elkazzaz et al,. 2021) . Retinoic acid insufficiency in the olfactory epithelium, both in mouse and chick models, causes progenitor cell maintenance failure and, consequently, olfactory neurons differentiation is not maintained . An explant system, showed that renewal of olfactory neurons is inhibited if retinoic acid synthesis was failed in the olfactory epithelium (Paschaki M et al., 2013) . It's worth noting that vitamin A shortage also causes olfactory and taste problems, In a study by Garrett-Laster et al., (1984), the patients had vitamin A deficiency because of malnutrition and alcoholic liver cirrhosis; they lost their sense of smell after that disorder. LaMantia and Rawson et al.,( 2007) reported that administration of retinoid acid after the damage of olfactory system motivates an immune response and produces a more quick recovery of olfactoryguided behavior. It was showed that Isotretinoin improved the significantly performance of patients in the olfactory test(Demet Kartal et al.,2017) Moreover, there is increasing evidence that retinoic acid (atRA) influences gene expression of components of renin-angiotensin system (RAS), which plays a pivotal role in the pathophysiology of essential hypertension. Retinoic acid induced ACE2 expression in different animal models. Moreover, a study suggests that topical retinoids may have applicability in promoting sinus regeneration and wound healing. In a study comparing treated and untreated nasal mucosa ,untreated regenerated mucosa showed expected changes of submucosal gland loss, basal lamina and lamina propria fibrosis and loss of cilia. Reinoic acid treatment appeared to result in better mucosal regeneration marked by less cellular atypia and fibrosis(Mendy S. Maccabee et al,. 2003).. Aerosolized retinoic acid will have an effective role in treating post COVID-19 anosmia (loss of smell) via upregulating ACE2, STRA 6 and regenerating of olfactory receptors and olfactory sensory cells and neurons.
Phase 4
Waitlist Available
Michelle OrzechowskiAmr Ahmed
5 Anosmia Clinical Trials Near Me
Top Hospitals for Anosmia Clinical Trials
Image of Duke University Medical Center in North Carolina.
Duke University Medical Center
Durham
1Active Trials
0All Time Trials for Anosmia
2023First Anosmia Trial
Image of Johns Hopkins Medicine in Maryland.
Johns Hopkins Medicine
Baltimore
1Active Trials
0All Time Trials for Anosmia
2023First Anosmia Trial
Image of Washington University in Missouri.
Washington University
Saint Louis
1Active Trials
0All Time Trials for Anosmia
2023First Anosmia Trial
Image of Michelle Orzechowski in Florida.
Michelle Orzechowski
Tampa
1Active Trials
0All Time Trials for Anosmia
2023First Anosmia Trial
Image of UPMC Children's Hospital of Pittsburgh in Pennsylvania.
UPMC Children's Hospital of Pittsburgh
Pittsburgh
1Active Trials
0All Time Trials for Anosmia
2023First Anosmia Trial
Top Cities for Anosmia Clinical Trials
Image of Durham in North Carolina.
Durham
1Active Trials
Duke University Medical CenterTop Active Site
Image of Baltimore in Maryland.
Baltimore
1Active Trials
Johns Hopkins MedicineTop Active Site
Anosmia Clinical Trials by Phase of Trial
N/A Anosmia Clinical Trials
1Active Anosmia Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Treatment
Anosmia Clinical Trials by Age Group
< 65 Anosmia Clinical Trials
1Active Anosmia Clinical Trials
Smell Retraining
Most Recent Anosmia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Beclomethasone for Post-Covid Hyposmia
9/5/2023
Phase 2
Treatment for Loss of Smell
2/1/2023
N/A
Gabapentin for COVID-19
1/10/2022
Phase 2
Aerosolized 13 cis retinoic acid and Vitamin D for Anomia
11/1/2021
Phase 4
Smell Retraining for Loss of Smell
9/30/2021
Phase 1 & 2
Top Treatments for Anosmia Clinical Trials
Treatment Name
Active Anosmia Clinical Trials
All Time Trials for Anosmia
First Recorded Anosmia Trial
Beclomethasone
1
1
2023
Treatment
1
1
2023
Gabapentin
1
1
2022
Aerosolized 13 cis retinoic acid and Vitamin D
1
1
2021
Smell Retraining
1
1
2021

What Are Anosmia Clinical Trials

Anosmia is a sensory disorder defined by loss of smell. The condition can indirectly impact taste, but it is not categorized as ageusia (loss of taste). For some, the condition is temporary, but for others, it can be permanent. Some people only lose some of their smell but retain some function.

According to Johns Hopkins, sense disorders can be a result of the following:

  • Illness, such as CoVid
  • Cocaine uses
  • Smoking cigarettes
  • Radiation therapy for throat or head cancers
  • Some medications
  • Nasal polyps
  • Dental issues
  • Hormone changes
  • Injuries to the head

Clinical trials for anosmia examine various methods to treat the condition, including smell retraining.

Why Is Anosmia Being Studied Through Clinical Trials?

According to the National Institute on Deafness and Other Communication Disorders, 23% of adults over 40 in the US had some alternation of smell. 12.4% had enough alteration to be considered measurable.

According to a 2023 paper in the Journal of NeuroVirology_, _instances of anosmia sharply increased in 2020 with the spread of CoVid-19. For some patients, the anosmia improves after 2-3 weeks. However, according to the Cleveland Clinic, 15% of patients still have a loss of smell 60 days later. Consequently, research into the disorder has risen, and many focuses on the most effective forms of smell retraining.

What Are The Types Of Treatments Available For Anosmia?

According to the Mayo Clinic, treatment for anosmia depends on the cause. For example, it clears up in a few days when it is caused by a cold or allergies. In addition, antibiotics are used to treat bacterial infections that cause loss of smell.

In the event there is a blockage, removing the item resolves the problem. However, sometimes the blockage is caused by inflammation rather than an object, polyps, or a tumor, and steroids can help.

However, not all anosmia can be treated.

CoVid-19 has brought new challenges to treating anosmia. According to a 2023 comprehensive review published in Cureus, researchers and healthcare providers are exploring many ways to help their patients regain their sense of smell. These potential treatments include some of the following:

  • Coffee
  • Intranasal insulin films
  • Minocycline
  • Corticosteroids
  • Melatonin
  • Nasal fluticasone spray
  • Nasal betamethasone drops
  • Olfactory training

However, these are still being studied, and some are showing more promising results than others.

What Are Some Recent Breakthrough Clinical Trials For Anosmia?

2023: Electrical Stimulation: Researchers at the Medical University of South Caroline investigated if electrical stimulation of the trigeminal nerve could improve olfaction. The study involved 20 healthy adults who, through randomization, were treated with trigeminal never stimulation (TNS), transcranial direct current stimulation (tDCDS), or sham.

Results showed that TNS is safe, simple, and noninvasive.

2023: Olfactory Training in CoVid-19 Patients – Researchers from Europe, including the Department of Otolaryngology at Polyclinic of Poitiers, ran a study in three medical centers in France, Belgium, and Italy to examine the effectiveness of olfactory training (OT) in people with dysfunction resulting from CoVid-19.

57 patients completed the entire 18-month evaluation process. Of that total, 32 adhered to the full OT training. The results concluded that the training provided better mid-term improvements.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: August 29th, 2023

References1 Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6. https://pubmed.ncbi.nlm.nih.gov/322535352 Hummel T, Rissom K, Reden J, Hähner A, Weidenbecher M, Hüttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009 Mar;119(3):496-9. doi: 10.1002/lary.20101. https://pubmed.ncbi.nlm.nih.gov/192357393 Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Huttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009 Mar;119(3):496-9. doi: 10.1002/lary.20101. https://pubmed.ncbi.nlm.nih.gov/192357394 Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist. 2021 Dec;27(6):582-603. doi: 10.1177/1073858420956905. Epub 2020 Sep 11. https://pubmed.ncbi.nlm.nih.gov/329146995 Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, Mularoni F, Gaudioso P, Cazzador D, Marciani S, Frasconi S, Ferraro M, Berro C, Varago C, Nicolai P, Tirelli G, Da Mosto MC, Obholzer R, Rigoli R, Polesel J, Hopkins C. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):729-732. doi: 10.1001/jamaoto.2020.1379. https://pubmed.ncbi.nlm.nih.gov/326144426 Mersfelder TL, Nichols WH. Gabapentin: Abuse, Dependence, and Withdrawal. Ann Pharmacother. 2016 Mar;50(3):229-33. doi: 10.1177/1060028015620800. Epub 2015 Dec 31. https://pubmed.ncbi.nlm.nih.gov/267216437 Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984 Feb;94(2 Pt 1):176-8. https://pubmed.ncbi.nlm.nih.gov/66944868 Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist. 2021 Dec;27(6):582-603. doi: 10.1177/1073858420956905. Epub 2020 Sep 11. Review. https://pubmed.ncbi.nlm.nih.gov/329146999 Damm M, Pikart LK, Reimann H, Burkert S, Goktas O, Haxel B, Frey S, Charalampakis I, Beule A, Renner B, Hummel T, Huttenbrink KB. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014 Apr;124(4):826-31. doi: 10.1002/lary.24340. Epub 2013 Sep 19. https://pubmed.ncbi.nlm.nih.gov/2392968710 Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984 Feb;94(2 Pt 1):176-8. doi: 10.1288/00005537-198402000-00004. https://pubmed.ncbi.nlm.nih.gov/6694486
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top